BRKR: Bruker EV/EBITDA Multiple

Corporate emblem and logo of Bruker (BRKR)

Bruker Corporation dominates the high-tech diagnostic equipment segment, where patent protection and instrument complexity create insurmountable barriers to entry for new players. The company's EV/EBITDA ratio demonstrates business valuation dynamics in a historical context, with the value 18.75 capturing the metric level. Clients become long-term captives of expensive ancillary services, while a stable staff of elite engineers ensures the preservation of unique competencies.

Bruker BioSpin - BRKR Enterprise Value to EBITDA Ratio (period 11/23/2025 - 11/17/2026)

Summary analytical data breakdowns for Bruker (BRKR)

- stock price and consensus target price:
Initial company analysis:Bruker BRKR
Original product of bruker.com

To protect capital from market noise, it is critical to utilize the EV/EBITDA metric, including depreciation and debt, which compares the total enterprise value of the business with its operating profit before taxes, excluding the impact of the debt load. The current value of 18.75 allows for an assessment of the scaling efficiency of Bruker Corporation (BRKR) within the mass spectrometry and spatial biology segments, determining the fair value of assets during its expansion into the medical diagnostics market.

Competitor analysis for Bruker Corporation

EV/EBITDA Multiple ABT (abbott.com)|Total Company Value to Operating Income Before Depreciation Ratio Thermo Fisher Scientific (TMO)|GE HealthCare Technologies Inc. - EV/EBITDA Multiple|Mettler-Toledo International Inc. (MTD) - Enterprise Value to EBITDA Ratio|WAT (Waters Corp.) - Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Ratio Bio-Techne Corporation|Enterprise Value to EBITDA Ratio AZTA|VREX: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Semler Scientific Inc (SMLR)|Enterprise Value to EBITDA Ratio Butterfly Network BFLY|EV/EBITDA Multiple MLAB (mesalabs.com)|QSI: Enterprise Value to Operating Income Before Depreciation|Nano-X - EV/EBITDA Multiple|QTRX (Quanterix Corporation) - Enterprise Value to Operating Income Before Depreciation|MASS: EV/EBITDA Multiple|CapsoVision Medical (CV) - EV/EBITDA Multiple|MXCT (MaxCyte Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Rapid Micro Biosystems (RPID)|EV/EBITDA Multiple SEER|EV/EBITDA Multiple hyperfine.io (HYPR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FONAR FONR|Business Value to Operating Income Before Depreciation DXR|MDAI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VIVS (Organovo Holdings, Inc.)|ACON: EV/EBITDA Multiple|Company Value to EBITDA Akoya (AKYA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization thermogenesis.com|TLIS - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio TTOO (T2 Biosystems Inc.)